Before we dive in, let’s make sure you’re set to receive The Daily Breakdown each morning. To keep getting our daily insights, all you need to do is log in to your eToro account.
Interested in more Deep Dive content? Check out our latest research.
Deep Dive
Eli Lilly is one of the world’s largest pharmaceutical companies, with a market value of roughly $1.1 trillion. It develops medicines across diabetes, obesity, cancer, immunology, and neuroscience, but is best known today for Mounjaro and Zepbound, its blockbuster treatments for diabetes and weight loss. Those drugs have become the company’s main growth engine, supported by products such as Verzenio, Jardiance, Taltz, and Alzheimer’s treatment Kisunla.
Its pipeline is led by next-generation obesity drugs, including retatrutide, as well as efforts to expand tirzepatide into additional metabolic and cardiovascular conditions. Lilly is also developing new treatments for Alzheimer’s disease, cancer, and inflammatory disorders.
Revenue has grown for eight straight years and is expected to keep rising. Profits have been less consistent, with sharp gains often followed by flat or weaker years. The chart above adds context through operating margins and ROIC, or how efficiently invested capital generates profit.
In other words, the company’s margin profile has strengthened over the last few years, while Eli Lilly has seen improved returns on its investments.
Future Growth Projections
Over the last three months and six months, earnings estimates for LLY have been revised higher by 4.3% and 7.1%, respectively. As earnings and revenue have improved over the past few years, analysts expect that to continue moving forward. According to Bloomberg, analysts project the following:
Earnings Growth: 46.4% in 2026, 27% in 2027, and 16% in 2028
Revenue Growth: 30.8% in 2026, 16.5% in 2027, and 12.7% in 2028
Analysts currently have a consensus price target of ~$1345 on LLY stock, implying about 14% upside to today’s stock price.
Want to receive these insights straight to your inbox?
Sign up here
Diving Deeper — Valuation
Eli Lilly’s valuation presents an interesting setup. Its forward earnings multiple remains well below the peaks reached during the height of GLP-1 enthusiasm, when LLY and peers such as Novo Nordisk surged to record highs. However, its current valuation range is still taking shape. Over the past year, the stock has found support around 23 to 25 times forward earnings — an area that previously acted as resistance — while the upper end remains less defined. Earlier this year, shares stalled near 35 times forward earnings.
At the same time, Lilly now has stronger margins, higher ROIC, and solid revenue and earnings growth. Shares recently reached record highs even as the valuation multiple approached its 2026 low, illustrating how quickly earnings — the “E” in the P/E ratio — have grown.
Risks
One of Lilly’s biggest risks is its growing reliance on Mounjaro and Zepbound. Those drugs drive much of the company’s growth, leaving results sensitive to competition, manufacturing constraints, safety concerns, or weaker-than-expected demand. Rival treatments and new obesity drugs could also pressure Lilly’s market share and pricing.
Access remains another key challenge, as many insurers and employers still limit coverage for weight-loss drugs. Lilly also faces the usual pharmaceutical risks, including failed clinical trials, regulatory delays, patent disputes, and pricing pressure. Given the stock’s premium valuation, even a modest setback could trigger an outsized reaction.
The Bottom Line
Eli Lilly has built one of the strongest growth stories in the pharmaceutical industry, supported by rapid revenue growth, improving profitability, and a broad pipeline. Its earnings expansion has also helped keep the stock’s valuation below prior peaks despite the stock’s recent move to record highs.
Bulls may focus on Lilly’s market leadership, improving fundamentals, and long runway for growth. Bears may point to rising competition, high expectations, and the risks that come with relying heavily on a few major growth drivers.
Disclaimer:
Please note that due to market volatility, some of the prices may have already been reached and scenarios played out.
